Amac: Kesitsel calismada Psikotik Bozukluklar Birimi'mizde takip edilen sizofreni hastalarinda metabolik sendrom (MetS) sikligini saptamak ve MetS sikligi ile hastalarin kullandiklari ilaclar arasindaki iliskiyi incelemek amaclanmistir. Yontem: Calismaya dahil edilen 87 sizofreni hastasinin aclik kan sekeri (AKS), yuksek dansiteli lipoprotein (High Density Lipoprotein, HDL) ve trigliserid (TG) degerleri ve o siradaki arteriyel kan basinclari, bel cevresi, boy ve kilolari degerlendirildi. Bulgular: MetS sikligi, Yetiskin Tedavi Paneli III (Adult Treatment Panel III, ATP III) tani olcutlerine gore %29.9, ATP III A'ya gore %35.6 ve Uluslararasi Diyabet Federasyonu (International Diabetes Federation, IDF) tani olcutlerine gore ise %42.5 olarak tespit edilmistir. Hastalarin %27.6' sinda MetS olcutlerinden ikisi pozitifti ancak MetS tanisini karsilamiyordu. MetS ile yas, hastaligin baslangic yasi ve hastalik suresi arasinda iliski yoktu. Tum tani olcutlerine gore erkeklerde MetS daha sikti ancak bu sadece IDF'ye gore istatistiksel olarak anlamliydi. Tekli ve coklu antipsikotik tedavisi alan hastalar arasinda MetS sikligi acisindan anlamli fark saptanmadi. Biperiden kullanan hastalarda MetS sikligi anlamli olarak kullanmayanlara gore daha dusuktu. Sonuc: Calismamizda MetS sikligi bazi calismalara gore dusuk oranlarda olsa da genel olarak sizofrenide bildirilmis oranlara benzerlik gostermektedir. Sizofreni hastalarinin takiplerinde ve tedavi seceneklerinde MetS ciddiyetle goz onune alinmalidir, gerekli durumlarda erken donemde risk azaltici mudahaleler yapilmalidir. Anahtar kelimeler: Sizofreni, metabolik sendrom, antipsikotikler Objective: In this cross-sectional study we aimed to determine the metabolic syndrome (MetS) prevalence in schizophrenia patients followed up in our Psychotic Disorders Unit, and to evaluate the relationship between MetS and medication of the patients. Method: High density lipoprotein (HDL), fasting glucose, triglyceride levels, arterial blood pressure and waist circumference at the level of the umbilicus of the patients included in the study were measured in 87 schizophrenia patients. Results: According to Adult Treatment Panel III (ATP III). ATP III A and International Diabetes Federation (IDF) criteria; metabolic syndrome prevalence was 29.9%, 35.6% and 42.5% respectively. 27.6% of patients had two criteria of MetS but did not meet MetS diagnosis. There was no association between MetS and age, age of onset of illness and duration of illness. Men had higher MetS prevalence according to all diagnostic criteria, however there was a statistical significance only for IDF. There was no difference of MetS prevalence between monotherapy and combined antipsychotic medications. The metabolic syndrome prevalence was significantly lower in biperiden users than in the nonuser patients Discussion: Although the prevalence of MetS is lower than in some previous studies, it is generally similar to other schizophrenia researches. MetS must be carefully considered in schizophrenia patients follow up and treatment choices, and some risk decreasing interventions must be made when necessary in the early period. Keywords: Schizophrenia, metabolic syndrome, antipsychotics